The Pharmacologic Basis for the Treatment of Endocrinopathic Laminitis

Summary

# Editorial Summary: Pharmacologic Management of Endocrinopathic Laminitis Whilst laminitis demands integrated intervention across veterinary, farriery, and nutritional disciplines, Durham's review examines the evidence base for pharmacological approaches specifically targeting endocrine-mediated disease—particularly pituitary pars intermedia dysfunction (PPID) and equine metabolic syndrome (EMS). Rather than detailing treatment protocols for acute laminitic episodes, the paper concentrates on drugs with potential preventative value in horses at heightened risk due to underlying endocrinopathy. Key pharmacological categories discussed include insulin-sensitising agents, dopamine agonists for PPID management, and anti-inflammatory medications, with consideration of how these interventions might interrupt the pathophysiological cascade leading to laminar failure. The practical significance lies in identifying which pharmaceutical strategies carry genuine evidence for prophylaxis versus those requiring further investigation, enabling veterinarians and their teams to make evidence-informed decisions about long-term management of metabolically compromised horses—particularly critical given that endocrinopathic laminitis represents a substantial proportion of laminitis cases in mature and aged populations. This framework supports a preventative approach rather than reactive treatment alone, potentially improving outcomes through early pharmacological intervention in predisposed individuals.

Read the full abstract on PubMed

Key Findings

• •Pharmacologic interventions can provide prophylactic benefit in endocrinopathic laminitis secondary to PPID and EMS
• •Treatment of laminitis requires multidisciplinary collaboration between veterinarians, farriers, and nutritionists
• •Management of underlying endocrine dysfunction is central to preventing laminitis in metabolically compromised horses

Conditions Studied